At the end of Q2, the biotech has a cash balance of $808 million and burned $95 million in the 1H of the year. Viking ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $23.94, demonstrating a +1.44% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...

Viking Therapeutics presents a high-risk, high-reward opportunity in the exploding GLP-1 weight loss market, where early clinical data for its VK2735 drug shows competitive results against current ...

Viking Therapeutics, Inc.'s VK2735 oral trial met efficacy and safety endpoints, but high discontinuation rates and modest weight loss disappointed Wall Street, triggering a steep sell-off. Despite ...

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering ...

Shares of Viking Holdings (NYSE:VIK) are under pressure Tuesday after Royal Caribbean (RCL), the second-largest cruise ...

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 12 unusual trades. Delving into the details, we ...

JP Morgan analyst Matthew Boss reiterated an Overweight rating on the shares of Viking Holdings Ltd (NYSE:VIK) and raised the price target to $58 from $50. From 2017 to 2019, VIK’s pre-pandemic annual ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...